Share Name Share Symbol Market Type Share ISIN Share Description
Profile Thera. LSE:PTP London Ordinary Share GB0001386225 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p - - - - - - - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 0.00

Profile Thera. Share Discussion Threads

Showing 101 to 123 of 125 messages
Chat Pages: 5  4  3  2  1
DateSubjectAuthorDiscuss
15/7/2004
15:48
Anyone know when we will see the cash from these ?
bbbbb
01/7/2004
06:18
RNS Number:3464A Respironics, Inc. 1 July 2004 Not for release, publication or distribution, in whole or in part, in, into or from the United States, Canada, Australia or Japan. Embargoed until 7:00 a.m. on 1 July 2004 Recommended Cash Offer by Respironics UK Holding Company Limited ("Respironics UK") for Profile Therapeutics plc ("Profile") Offer declared unconditional in all respects The board of Respironics UK announces that the recommended cash offer (the " Offer") made by Bridgewell Limited on behalf of Respironics UK for the entire issued and to be issued share capital of Profile as set out in the Offer document dated 21 May 2004 (the "Offer Document") has been declared unconditional in all respects and the remaining conditions have been satisfied or waived. The Offer will remain open until further notice. Profile Shareholders who have not yet accepted the Offer are encouraged to complete and return the Form of Acceptance as soon as possible so as to be received either by post or by hand by Capita IRG Plc, Corporate Actions, PO Box 166, The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TH. Respironics UK intends to implement the procedures set out in Sections 428 to 430F (inclusive) of the Companies Act 1985 to acquire compulsorily any outstanding Profile Shares to which the Offer relates. Respironics UK also intends, subject to any applicable requirements of the UK Listing Authority, to procure that Profile applies to the London Stock Exchange for the admission to trading of the Profile Shares to be cancelled. Such cancellation will take effect no earlier than 20 business days from the date of this announcement and is expected to significantly reduce the liquidity and marketability of any Profile Shares not assented to the Offer. By 3:00 pm on 30 June 2004, valid acceptances had been received in respect of a total of 48,353,256 Profile Shares, representing approximately 98.39 per cent. of the existing issued share capital of Profile. During the Offer Period Respironics UK obtained irrevocable undertakings to accept the Offer from certain Profile Shareholders (including the Directors of Profile) in respect of 30,587,783 Profile Shares representing in aggregate approximately 62.2 per cent. of the existing issued share capital of Profile. Respironics UK has received valid acceptances in respect of all Profile Shares to which these undertakings related. Neither Respironics UK, nor any person acting, or deemed to be acting, in concert with Respironics UK for the purpose of the Offer owned, or controlled, any Profile Shares or any rights over any Profile Shares immediately prior to the commencement of the Offer Period. Save as disclosed in this announcement, neither Respironics UK nor any person acting, or deemed to be acting, in concert with Respironics UK has acquired or agreed to acquire Profile Shares (or rights over Profile Shares) during the Offer Period. Unless the context otherwise requires, defined terms used in this announcement shall have the same meanings given to them in the Offer Document. Enquiries: Respironics, Inc. Dan Bevevino (Vice President and CFO) +1 724 387 5235 Maryellen Bizzack (Director, Marketing & Communications) +1 724 387 5006 Bridgewell Limited John Craven (Director) 020 7003 3108 Profile Therapeutics plc John Lisle (Chief Executive Officer) 0870 770 2004 PricewaterhouseCoopers LLP Darren Bryant (Director) 020 7804 4089 Bridgewell, which is regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Respironics, Inc. and Respironics UK and no one else in connection with the Offer and will not be responsible to anyone other than Respironics, Inc. and Respironics UK for providing the protections afforded to its customers or for providing advice in relation to the Offer or in relation to the contents of this announcement or any transaction or arrangement referred to herein. PricewaterhouseCoopers LLP, which is authorised and regulated in the United Kingdom by the Financial Services Authority for designated investment business, is acting exclusively for Profile and for no one else in relation to the Offer and will not be responsible to anyone other than Profile for providing the protections afforded to clients of PricewaterhouseCoopers LLP or for giving advice in relation to the Offer or any other matter referred to in this announcement. This announcement does not constitute an offer to sell or an invitation to purchase or subscribe for any securities or the solicitation of an offer to buy or subscribe for any securities pursuant to the Offer or otherwise. The Offer is being made solely by the Offer Document and the Form of Acceptance accompanying the Offer Document, which contain the full terms and conditions of the Offer, including details of how the Offer may be accepted. The laws of relevant jurisdictions may affect the availability of the Offer to persons not resident in the United Kingdom. Persons who are not resident in the United Kingdom, or who are subject to the laws of any jurisdiction other than the United Kingdom, should inform themselves about, and observe, any applicable legal and regulatory requirements. The Offer is not being made, directly or indirectly, in or into the United States or by use of the mails of, or by any means or instrumentality (including, without limitation, facsimile or other electronic transmission, telex or telephone) of inter-state or foreign commerce of, or any facility of, a national, state or other securities exchange of, the United States, nor is it being made directly or indirectly in or into Canada, Australia or Japan and the Offer cannot be accepted by any such use, means, instrumentality or facility or from within the United States, Canada, Australia or Japan or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction. Accordingly, copies of this press announcement, the Offer Document and the Form of Acceptance are not being, will not be and must not be mailed or otherwise forwarded, distributed or sent in, into or from the United States, Canada, Australia or Japan or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction and persons receiving this press announcement, the Offer Document and Form of Acceptance (including without limitation custodians, nominees and trustees) must not mail, forward, distribute or send them in, into or from the United States, Canada, Australia or Japan or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction. This information is provided by RNS The company news service from the London Stock Exchange END OUPBRGDLIDXGGSG Profile Thera.(PTP)
maywillow
21/5/2004
07:56
(Updates with company quotes, financial advisors, details on Respironics) MURRYSVILLE, PA (AFX) - Respironics Inc said it will offer 50.9 pence per share or a total of about 44.6 mln usd in cash for Profile Therapeutics PLC, valuing the UK group at 25 mln stg. The acquisition has been approved by the boards of directors of both Profile Therapeutics and Respironics, and shareholders representing about 66 pct of Profile Therapeutics' outstanding shares have indicated their support for the transaction, subject to certain limitations, Respironics said. Completion of the acquisition is expected around the end of the second quarter of calendar year 2004, which is Respironics' 2004 fourth quarter. Profile, currently Respironics' distributor for sleep and ventilation products in the UK, will become a wholly owned subsidiary of Respironics. Respironics estimates the acquisition will add 15-20 mln usd to its annual revenues, and will be neutral to earnings per share during fiscal years 2004 and 2005. The acquisition is expected to be modestly accretive in fiscal year 2006, adding approximately 0.02-0.03 usd per share. The offer is subject to customary closing conditions. "The offer builds on the relationship between Respironics and Profile, which has run for over 15 years," Profile chairman Mark Kirby said. "It provides the business with a strong long-term partner for the future to develop further the commercial opportunities for Profile's current product ranges." Parker/Hunter Inc and Bridgewell Ltd are financial advisers to Respironics and PricewaterhouseCoopers is acting for Profile Therapeutics. Respironics is a US-based developer, manufacturer and marketer of medical devices used in the treatment of patients suffering from sleep and respiratory disorders. etain.lavelle@afxnews.com el/ra
grupo guitarlumber
21/5/2004
07:26
Shame realy as the company would have done very well over the years.
zapa
21/5/2004
07:16
It looks like we are getting 50.9p per share. It looks okay when you read through the offer document. A fair price in current circumstances...
beckaroo
21/4/2004
18:18
good call ntv....judging by the share price the talks may be collapsing or some of the conditions outlined have not been met.
bbbbb
21/4/2004
18:13
looking promising
ntv
26/3/2004
21:44
might get back in if bid talks collapse
ntv
26/3/2004
21:41
sold out final lot today reinvesting proceeds in anc
ntv
23/3/2004
18:27
was in the Ivestor chroncile this week as good value so should pick up now
robg28
21/3/2004
19:55
bidder might be happy to pick up stock to help pay for its costs if higher cash bid comes along 3i happy to sell some incase bid fails
ntv
20/3/2004
09:08
gopher I wondered the same but what good would that amount do?
zapa
19/3/2004
21:44
3I makes a substantial disposal in the market today - To the bidder?
gopher
19/3/2004
07:42
Proxim regulatory approval is due soon.
bbbbb
18/3/2004
22:57
we have seen a number of technology groups sell out much to the disgust of the shareholders. (psion and biocompatibles) but Profile has not had such a high reputation or share price. I can't see the point of selling a company with turnover, no debt and a high R&D spend over the past few years at the current market cap.
gopher
18/3/2004
20:58
i hope so kombimatec as 50p is far from generous offer are evo invlved somewhere along the line or are they house broker
ntv
18/3/2004
16:07
I'm not sure it will satisfy 3i or other major shareholders who would not get back even half their investment. Hopefully this statement will bring other potential buyers in to the ring.
kombimatec
18/3/2004
16:02
your right there,thats why whoever has moved now.
zapa
18/3/2004
15:59
spot on but the offer is not good enough
ntv
18/3/2004
15:40
ah ah... Profile Therapeutics plc ("Profile" or "the Company") The Board of Profile has noted the recent rise in the Company's share price and announces that it is in discussions that may or may not lead to a recommended cash offer being made for the Company. These discussions relate to a proposed offer at a price at or around the current share price of 50 pence and that the approach remainssubject to a number of pre-conditions. Shareholders should therefore note that, at this stage, there is no certainty as to the level of any such offer or indeed whether any firm offer will actually be made. This announcement is issued by the Board of Profile and not on behalf of the potential offeror. The Board of Profile is being advised by PricewaterhouseCoopers LLP.
bbbbb
18/3/2004
15:39
v strange day indeed. 2 million sells and the price rises 10%.
bbbbb
18/3/2004
14:02
more like it please
zapa
18/3/2004
12:26
what's going on here?
todworth
Chat Pages: 5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20161204 14:19:46